
TOVX
Healthcare · Biotechnology · $6.6M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | — | -0.03 | — |
| Aug 11, 2026 | Before the open | -0.05 | -0.07 | -40.0% |
| May 5, 2026 | After the close | -0.05 | -0.05 | 0.0% |
| Mar 12, 2026 | Time not confirmed | -0.37 | -0.10 | +73.5% |
| Nov 12, 2025 | Before the open | -0.38 | -0.45 | -18.4% |
| Aug 14, 2025 | Before the open | -0.47 | -1.93 | -310.6% |
| May 14, 2025 | Before the open | -1.56 | -1.55 | +0.6% |
| Mar 24, 2025 | Before the open | -7.22 | -11.49 | -59.1% |
| Nov 12, 2024 | Before the open | -5.25 | -6.81 | -29.7% |
| Aug 13, 2024 | Before the open | -4.75 | -10.75 | -126.3% |
| May 7, 2024 | Before the open | -8.50 | -7.50 | +11.8% |
| Mar 25, 2024 | Before the open | -0.41 | -0.34 | +17.1% |
| Nov 13, 2023 | Before the open | -8.50 |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian…
| -4.75 |
| +44.1% |
| Aug 8, 2023 | Before the open | -8.50 | -8.50 | 0.0% |
| May 11, 2023 | Before the open | -8.00 | -7.50 | +6.3% |
| Mar 30, 2023 | Before the open | -0.33 | -0.33 | 0.0% |
| Nov 10, 2022 | After the close | -11.25 | -8.25 | +26.7% |
| Aug 11, 2022 | Before the open | -7.50 | -7.75 | -3.3% |
| May 16, 2022 | Before the open | -0.30 | -0.30 | 0.0% |
| Mar 16, 2022 | After the close | -5.00 | -10.00 | -100.0% |
| Nov 3, 2021 | After the close | -5.00 | -5.00 | 0.0% |
| Aug 5, 2021 | After the close | -5.00 | -5.00 | 0.0% |
| May 5, 2021 | After the close | -5.00 | -32.50 | -550.0% |
| Mar 4, 2021 | After the close | -0.80 | -1.40 | -75.0% |
| Nov 10, 2020 | After the close | -40.00 | -35.00 | +12.5% |
| Aug 6, 2020 | After the close | -35.00 | -45.00 | -28.6% |
| May 5, 2020 | After the close | -2.70 | -1.70 | +37.0% |
| Feb 20, 2020 | After the close | -57.50 | -47.50 | +17.4% |
| Nov 4, 2019 | After the close | -57.50 | -77.50 | -34.8% |
| Aug 8, 2019 | After the close | -2.30 | -2.20 | +4.3% |
| May 8, 2019 | After the close | -2.30 | -2.20 | +4.3% |
| Feb 27, 2019 | After the close | -48.75 | -332.50 | -582.1% |
| Nov 8, 2018 | After the close | -525.00 | -232.50 | +55.7% |
| Aug 8, 2018 | After the close | -350.00 | -262.50 | +25.0% |
| May 8, 2018 | After the close | -437.50 | -175.00 | +60.0% |
| Feb 22, 2018 | Before the open | -16.33 | 7.00 | +142.9% |